publication . Article . 2006

Incretin mimetics as a novel therapeutic option for hepatic steatosis

Maarten E. Tushuizen; Mathijs C. Bunck; Petra J. W. Pouwels; Jan Hein T.M. van Waesberghe; Michaela Diamant; Robert J. Heine;
Open Access English
  • Published: 01 Oct 2006 Journal: Liver International, volume 26, issue 8, pages 1,015-1,017 (issn: 1478-3223, Copyright policy)
  • Country: Netherlands
Abstract
Abstract: Background: Fat accumulation in the liver or non-alcoholic fatty liver disease (NAFLD) is regarded as a key pathogenic factor and component of the metabolic syndrome. It was reported that administration of the incretin mimetic exenatide reversed hepatic steatosis in an obese mouse model. We had the opportunity to study the effect of additional exenatide administration on liver fat content in a patient with type 2 diabetes. Case report: A 59-year-old male with poorly controlled type 2 diabetes was treated with exenatide in addition to metformin monotherapy. Following 44 weeks of exenatide therapy, mean the liver fat measured by liver spectroscopy declin...
Persistent Identifiers
Subjects
free text keywords: Hepatic steatosis, Incretin mimetics, Metabolic syndrome, Type2 diabetes, Hepatology, Metabolic syndrome, medicine.disease, medicine, Population, education.field_of_study, education, Endocrinology, medicine.medical_specialty, Metformin, medicine.drug, business.industry, business, Steatosis, Insulin resistance, Type 2 diabetes, Internal medicine, Exenatide, Fatty liver
Related Organizations
Download fromView all 5 versions
Open Access
ZENODO
Article . 2006
Provider: ZENODO
Restricted
NARCIS
Article . 2006
Provider: NARCIS
Any information missing or wrong?Report an Issue